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Abstract
Background: In Mozambique during 2004–2007 numbers of adult patients ($15 years old) enrolled on antiretroviral
therapy (ART) increased about 16-fold, from ,5,000 to 79,500. All ART patients were eligible for co-trimoxazole. ART
program outcomes, and determinants of outcomes, have not yet been reported.
Methodology/Principal Findings: In a retrospective cohort study, we investigated rates of mortality, attrition (death, loss to
follow-up, or treatment cessation), immunologic treatment failure, and regimen-switch, as well as determinants of selected
outcomes, among a nationally representative sample of 2,596 adults initiating ART during 2004–2007. At ART initiation,
median age of patients was 34 and 62% were female. Malnutrition and advanced disease were common; 18% of patients
weighed ,45 kilograms, and 15% were WHO stage IV. Median baseline CD4
+ T-cell count was 153/mL and was lower for
males than females (139/mL vs. 159/mL, p,0.01). Stavudine, lamivudine, and nevirapine or efavirenz were prescribed to 88%
of patients; only 31% were prescribed co-trimoxazole. Mortality and attrition rates were 3.4 deaths and 19.8 attritions per
100 patient-years overall, and 12.9 deaths and 57.2 attritions per 100 patient-years in the first 90 days. Predictors of attrition
included male sex [adjusted hazard ratio (AHR) 1.5; 95% confidence interval (CI), 1.3–1.8], weight ,45 kg (AHR 2.1; 95% CI,
1.6–2.9, reference group .60 kg), WHO stage IV (AHR 1.7; 95% CI, 1.3–2.4, reference group WHO stage I/II), lack of co-
trimoxazole prescription (AHR 1.4; 95% CI, 1.0–1.8), and later calendar year of ART initiation (AHR 1.5; 95% CI, 1.2–1.8). Rates
of immunologic treatment failure and regimen-switch were 14.0 and 0.6 events per 100-patient years, respectively.
Conclusions: ART initiation at earlier disease stages and scale-up of co-trimoxazole among ART patients could improve
outcomes. Research to determine reasons for low regimen-switch rates and increasing rates of attrition during program
expansion is needed.
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Introduction
Globally, during 2004–2009, the number of HIV-infected
patients enrolled on antiretroviral therapy (ART) increased more
than 10-fold, from less than 400,000 to more than five million, with
most new ART patients enrolled in sub-Saharan Africa [1].
Reporting treatment outcomes of patients enrolled in ART
programs is important to demonstrate program effectiveness and
justifycontinuedfunding,whileassessmentoffactorsassociated with
outcomes can help to identify opportunities for program improve-
ment [2,3]. Although many sub-national ART programs in sub-
Saharan Africa have reported their treatment experience [4–12],
onlya few studies canbe considerednationallyrepresentative dueto
the large cohort size [6,12], or sampling design [13].
In Mozambique, where about 1.6 million people are HIV-
infected and about 473,000 need ART [14], numbers of adult
patients ($15 years old) enrolled on ART increased about 16-
fold from less than 5,000 to 79,500 during 2004–2007 [15]. We
conducted a retrospective, cohort study among a nationally
representative sample of adult ART patients starting ART
during 2004–2007, to describe mortality rates, attrition rates
(numbers of patients who died, were lost to follow-up [LTFU],
or stopped ART per 100 person-years), immunologic treatment
failure rates, and determinants of attrition and treatment failure.
Secondary treatment outcomes of interest were CD4
+ T-cell
(CD4) count response and weight gain. Regimen-switch rates
were measured to allow comparison with rates reported from
other programs.
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Ethics Approval
This study was approved by the Institutional Review Board
(IRB) of the United States Centers for Disease Control and
Prevention (CDC) and the Mozambican Ethics Review Commit-
tee (Ministerio da Saude Comite Nacional de Bioetica para a Saude). Both
review boards approved the consent procedures. Patient informed
consent was not required as only routine, anonymous, operational
monitoring data were collected and analyzed.
Eligibility for ART during 2004–2007
During 2004–2007, patients diagnosed with World Health
Organization (WHO) stage IV disease, stage III disease with CD4
counts ,350/mL, or stage I or II disease with CD4 counts ,200/
mL, were eligible for ART [16]. Prescription of trimethoprim-
sulfamethoxazole combination, or co-trimoxazole (CTX), was
indicated for all ART patients. First-line ART regimens included
two nucleoside reverse-transcriptase inhibitors (NRTI) and a non-
nucleoside reverse transcriptase inhibitor (NNRTI). Second-line
regimens contained a protease inhibitor and two new NRTIs.
Before initiating ART, HIV counseling and testing (HIV-CT) of
patient partners was recommended to facilitate HIV care for
infected partners or prevention interventions for sero-discordant
couples.
Patient Monitoring
At ART initiation, standardized medical records, recommended
by the Ministry of Health (MOH), were completed. These records
captured, among other variables: date of visit, sex, age at
enrollment, date of birth, marital status, employment status,
HIV status of partner, WHO stage, CD4 count, weight, height,
hemoglobin level, ART regimen and CTX prescription status. At
all subsequent visits, the date of the visit, patient weight, clinical
stage and ART regimen prescribed were recorded, while at 6-
monthly intervals after ART initiation, hemoglobin measure-
ments, and CD4 counts were recommended to monitor disease
progression or improvement. Patients collected medications
monthly from clinic pharmacies where the date of scheduled
antiretroviral (ARV) pick-up appointments and actual ARV pick-
up occurrences were documented.
As in other resource-constrained settings where viral load
monitoring is not routine [6,13,17], during 2004–2008, treatment
failure was detected using clinical and immunologic criteria. A
new or recurrent stage III or IV condition was considered clinical
evidence of possible treatment failure; however, confirmation of
failure, with a CD4 measurement, was required before switching
regimens. All facilities providing ART had access to CD4 assays.
Immunologic failure criteria included a CD4 count decline from
baseline, a CD4 count ,100/mL, or a 50% decline from peak
CD4 count, after $6 months of therapy [16]. At the limited
number of sites with access to viral load testing facilities, viral load
measurements were also encouraged.
Treatment Outcome Measures
Our reported mortality rate represents the number of
documented deaths during ART per 100 person-years of observed
therapy. The attrition rate represents the number of patients lost
through attrition (death, LTFU, or stopping ART) per 100 person-
years of observed therapy. A patient absent from a health facility
in the 90 days preceding data abstraction was considered LTFU,
unless the medical record stated that the patient had died, stopped
ART, or transferred. The date of LTFU was recorded as the date
of the most recent visit, or one day after ART initiation if patients
only attended the initiation visit. One-year attrition proportions
are reported to allow comparison with published literature [11,18].
Patients transferring to other facilities during the first treatment
year were excluded from the one-year attrition proportion.
Transfers were censored from time-to-event analyses at the date
of transfer.
To allow comparison with other resource-constrained programs
[6,17], we report incidence of the first CD4 count meeting
immunologic treatment failure criteria. Incidence of clinical failure
is not reported because MOH guidelines required that the often
inaccurate diagnosis of clinical failure [19] be confirmed with
objective CD4 count measurements before a regimen change was
considered. To allow comparison with other programs in resource-
limited settings, we also report rates of regimen-switch per 100
patient-years [20].
CD4 counts were determined using FlowCount PLG CD4 assay
and analyzed with Beckman Coulter Epics XL-MCL Flow
Cytometers (both Beckman Coulter, Inc., Johannesburg, South
Africa). Blood Hemoglobins were determined with an automated
hematology analyzer, Sysmex XT2000i (Sysmex Europe, Inc.,
Hamburg, Germany) or HemoCue photometer assay (HemoCue
AB, Helsingborg, Sweden).
Similar to other cohort studies in resource-constrained settings
[6], adherence to ART was estimated by measuring timeliness of
patient visits to scheduled medicine pick-up appointments at
clinic-based pharmacies [21–23] during the first six months of
ART.
Study Design and Population
A retrospective cohort study design was used. Patient-level data
were abstracted from standardized, MOH-recommended medical
records onto study questionnaires by trained abstractors in
November 2008. Only medical records of adult patients, $15
years old at ART initiation, who started ART during 2004–2007,
were eligible.
Sample Size
Sample size calculations were performed using Epi Info
TM
software (CDC, Epi Info 2008, Version 3.5.1, Atlanta, GA). To
achieve a 95% confidence interval (CI) of 63.0% around the
estimate for 6-month attrition, assuming a design effect of 1.5, and
a conservative (i.e. higher than expected) 6-month attrition
proportion of 25% [11], a sample size of $1,200 patient records
was needed. This study was linked with a cost-effectiveness study;
we aimed to sample 2,600 medical records to meet the needs of
both studies.
Sampling
During study planning in November 2007, MOH-reported data
from the end of December 2006 were used to define the clinic
sample frame. By December 2006, 43,295 adults had initiated
ART at 152 clinics, all of which were managed by the MOH with
funding support from several donor agencies including the U.S.
President’s Emergency Plan for AIDS Relief (PEPFAR). Clinics
that had initiated ,50 adults on ART by this time were excluded
from the sample frame, resulting in 58 clinics, ranging in size from
1–49 adult ART enrollees and supporting only 1,061 adult ART
patients, being excluded. Ninety-four clinics, which had each
enrolled between 50 and 3,530 adult ART patients, were included
in the sample frame; of these clinics, 12 with .1,000 enrollees
were selected with certainty, while 18 with 50–1,000 enrollees
were selected using probability-proportional-to-size sampling. All
11 provinces in Mozambique were represented by the sample with
at least one ART clinic selected from each province. From the 30
Four-Year Adult ART Outcomes, Mozambique
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enrollees, we aimed to randomly sample 2,600 medical records.
Analytic Methods
Data were analyzed using SAS 9.2 (SAS Institute Inc., Cary,
NC), STATA 10 (StataCorp, 2009, Stata Statistical Software,
Release 10, College Station, TX), and SUDAAN (Research
Triangle Institute, 2005, SUDAAN, Release 9.0.1. Research
Triangle Park, NC). Data were weighted and survey design
controlled for, during analysis.
Multiple imputation with chained equations was used to impute
missing baseline demographic and clinical data [24]. The ice [25–
27] procedure in Stata was used to create 20 imputed datasets for
each of two outcomes included in multivariable analysis: Attrition
and treatment failure. The imputation model included the event
indicator, all study variables, and the Nelson-Aalen estimate of
cumulative hazard [28]. Missing data were assumed missing at
random (MAR) and all patients had complete time-to-event data.
When comparing baseline characteristics among groups, the x
2
and t-test were used to compare categorical and continuous
variables, respectively. Kaplan-Meier curves were used to examine
retention proportions stratified by baseline variables. Cox
proportional hazards regression models were used to estimate
unadjusted and adjusted hazard ratios (AHRs), 95% CIs, and p-
values. The proportional hazards assumption was assessed
separately for each imputed dataset using visual methods and
the Grambsch and Therneu test [29]. Estimates were combined
across the imputed datasets according to Rubin’s rules [24]. This
was accomplished using SUDAAN and the mim procedure in
Stata [30].
As a secondary analysis, mean CD4 count and weight change
over time was estimated to allow comparison with published
literature. SAS PROC MIXED was used to fit unweighted
polynomial growth curve models with maximum likelihood (ML)
estimation to the data [31]. Random effects were specified on the
intercept and slope terms. Predicted means and 95% CIs from the
polynomial growth curve models were plotted to graphically
illustrate change over time.
Results
Characteristics at ART Initiation
Data from medical records of 2,596 eligible, adult ART patients
were abstracted and analyzed. Table 1 illustrates analysis results
for both original and imputed datasets; in the following text,
weighted imputed data are reported unless otherwise stated.
At ART initiation, median age of patients was 34 years, and
62% were female of whom 16% (95% CI, 6–25%) were pregnant.
About 53% (95% CI, 50–57%) of patients were married or in a
civil union. Partner sero-status was documented in 13% (95% CI,
11–15%) of all records. In un-weighted analysis, 37 (11%) of 330
tested partners were sero-negative.
Active tuberculosis (TB) was frequent at ART initiation with
11% of patients receiving TB treatment. Many patients were
underweight; 18% weighed ,45 kilograms (kg) at ART start.
Advanced disease was common with 15% of patients diagnosed as
having WHO stage IV disease.
Median CD4 count at ART initiation was 153/mL; 16% (95%
CI, 14–19%) had counts below 50/mL and 50% (95% CI, 47–
54%) had counts ranging from 50–200/mL. Median CD4 counts
at ART initiation were lower for males than females (139/mL vs.
159/mL, p,0.01).
Median hemoglobin at ART initiation was 10.3 g/dL. Severe
anemia (hemoglobin ,8 g/dL) was present in 13% (95% CI, 12–
15%) of patients. Median hemoglobin at ART initiation was lower
for women than men (9.9 vs. 11.0 g/dL, p,0.01).
Stavudine (d4T), lamivudine (3TC), and nevirapine (NVP) or
efavirenz (EFV) comprised 88% of first-line regimens. Only 31%
(95% CI, 26–36%) of patients were prescribed CTX at ART
initiation; 3% (95% CI, 2–3%) were not prescribed CTX due to
allergy.
Mortality and Attrition
Of 2,596 patients sampled, 164 died, 564 were LTFU, and 10
stopped ART indefinitely during 4,001 patient-years of follow-up.
Median follow-up duration was 1.3 years (interquartile range, 0.7–
2.2 years). Of patients who died, 56% (95% CI, 49–63%) died
within 90 days of starting ART. Of patients who were LTFU, 41%
(95% CI, 35–48%) were lost within 90 days of starting ART.
Mortality rates were 3.4 deaths per 100 patient-years overall
(95% CI, 2.8–4.2), 12.9 deaths per 100 patient-years in the first 90
days (95% CI, 9.9–17.1), and 1.8 deaths per 100 patient-years
after 90 days (95% CI, 1.3–2.4).
One-year attrition was 21% (95% CI, 17–25%) with 15% LTFU
(95% CI, 11–18%), 5% dead (95% CI, 4–6%), and 1% stopping
ART (95% CI, 0–3%). Attrition rates were 19.8 attritions per 100
patient-years overall (95% CI, 17.9–21.9), 57.2 attritions per 100
patient-years in the first 90 days (95% CI, 49.5–66.4), and 13.2
attritions per 100 patient-years after 90 days (95% CI, 11.7–15.0).
Male sex was associated with attrition (AHR 1.5; 95% CI, 1.3–
1.8) (Table 2, figure 1A). Attrition risk decreased as age at ART
initiation increased (AHR associated with a 10-year age increase
was 0.8; 95% CI, 0.8–0.9). Patients starting ART one calendar
year later had higher attrition rates (AHR 1.5; 95% CI, 1.2–1.8).
Compared to patients with baseline WHO stage I/II, patients with
stage IV were at higher attrition risk (AHR 1.7; 95% CI, 1.3–2.4)
(Table 2, figure 1B). Patients with weight ,45 kg (AHR 2.1; 95%
CI, 1.6–2.9) (Table 2, figure 1C), and severe anemia (AHR 1.6;
95% CI, 1.2–2.1) were at higher attrition risk.
Patients not prescribed CTX were at higher risk for attrition
compared with patients who were prescribed this drug (AHR 1.4;
95% CI, 1.0–1.8) (Table 2, Figure 1D).
Immunologic Treatment Failure and Regimen Switch
Of 2,596 patients at risk, 486 experienced immunologic treatment
failure during 3,481 patient-years of follow-up. The failure rate was
14.0 failures per 100-patient years (95% CI, 13.0-16.0). The regimen-
switch rate was 0.6 per 100-patient years (95% CI, 0.4-1.1).
Predictors of immunologic treatment failure included male sex
(AHR 1.4; 95% CI, 1.2–1.8) and being single or widowed (AHR
1.3; 95% CI, 1.2–1.5). Risk of immunologic failure decreased as
age at ART initiation increased (AHR associated with a 10-year
age increase was 0.9; 95% CI, 0.8–1.0).
CD4 Count and Weight Response
Modeled mean gains in CD4 count were 173, 186, 237, 273,
and 293/mL at 6, 12, 24, 36 and 48 months of follow-up,
respectively (Figure 2A). Compared with males, females tended to
start ART with higher CD4 counts and maintain higher counts
during the first three treatment years (Figure 2B). Modeled mean
weight gains were 2.8, 3.8, 3.8, 3.9 and 3.6 kilograms at 6, 12, 24,
36 and 48 months of therapy (Figure 3A) and were similar for
males and females (Figure 3B).
Adherence
About 71% (95% CI, 66–77%) of patients were $95% adherent
to ART medicine pick-up appointments during the first six months
Four-Year Adult ART Outcomes, Mozambique
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Original Data
Following Multiple
Imputation (N=2,596)
Un-weighted
Frequency of
Observations
Un-
weighted
Total
Weighted Median with IQR*, or,
Percentage with 95% CI
Weighted Median with IQR*,
or, Percentage with 95% CI
Median Age
{, No., N, median (IQR)
Both Sexes 2,596 2,596 34 (28–42) 34 (28–42)
Female 1,576 1, 576 32 (27–39) 32 (27–39)
Male 1,020 1,020 38 (31–45) 38 (31–45)
Female
{, No., N, %, (95% CI) 1,576 2,596 62% (59–65%) 62% (59–65%)
Employment status, No., N, %, (95% CI)
Employed 992 2,268 46% (40–51%) 45% (40–51%)
Student 107 2,268 4% (3–5%) 4% (3–5%)
Unemployed 1,169 2,268 50% (45–56%) 51% (46–56%)
observations missing data** 328 2,596 13%
Active TB, No., N, %, (95% CI) 267 2,564 11% (9–13%) 11% (9–13%)
observations missing data** 32 2,596 1%
WHO Stage, No., N, %, (95% CI)
I/II 619 1,617 37% (32–42%) 40% (34–45%)
III 739 1,617 47% (43–52%) 45% (40–50%)
IV 259 1,617 16% (13–18%) 15% (13–18%)
observations missing data** 979 2,596 38%
Weight Category, No., N, % (95% CI)
,45 kg 367 2,061 17% (14–20%) 18% (15–21%)
45–60 kg 1,224 2,061 59% (56–61%) 57% (54–59%)
. 60 kg 470 2,061 24% (21–27%) 25% (22–28%)
observations missing data** 535 2,596 21%
BMI,18.5, No., N, %, (95% CI) 354 1,200 28% (23–33%) 28% (23–33%)
observations missing data** 1,396 2,596 54%
CD4
+ T-cell count, No., N, median (IQR)
Both Sexes 2,254 2,596 155 (76–231) 153 (74–231)
Female 1,373 1,576 161 (88–244) 159 (87–243)
Male 881 1,020 141 (59–213) 139 (59–213)
observations missing data** 342 2,596 13%
Hemoglobin, No., N, median (IQR)
Both Sexes 1,899 2,596 10.1 (8.8–11.6) 10.3 (8.8–11.7)
Female 1,182 1,576 9.8 (8.6–11.0) 9.9 (8.5–11.1)
Male 717 1,020 11.1 (9.0–12.5) 11.0 (9.2–12.5)
First Line ART Regimens
{, No., N, %, (95% CI)
D4T + 3TC + NVP/EFV 2,315 2,596 88% (82–94%) 88% (82–94%)
AZT + 3TC + NVP/EFV 240 2,596 11% (5–16%) 11% (5–16%)
D4T/AZT + 3TC + ABC 17 2,596 ,1% (0–1%) ,1% (0–1%)
Other 24 2,596 ,1% (0–1%) ,1% (0–1%)
Abbreviations: CI, confidence interval; IQR, interquartile range; TB, tuberculosis; WHO, World Health Organization; Kgs, kilograms; BMI, body mass index; ART,
antiretroviral therapy; D4T, stavudine; 3TC, lamivudine; NVP, nevirapine; EFV, efavirenz; AZT, zidovudine; ABC, abacavir; CTX, co-trimoxazole.
*Median and IQR calculated across 20 imputed datasets.
{Variables with complete data.
**Unweighted sample estimate.
doi:10.1371/journal.pone.0018453.t001
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Attrition* Immunologic Treatment Failure*
Original Following Multiple Imputation (N=2,596) Original Following Multiple Imputation (N=2,596)
Rate/100PY HR (95% CI) AHR
{ (95% CI) Rate/100PY HR (95% CI) AHR
{ (95% CI)
Sex
Female 1,576 17.9 1.0 1.0 1,576 13.1 1.0 1.0
Male 1,020 23.0 1.3 (1.1–1.4) 1.5 (1.3–1.8) 1,020 15.5 1.2 (1.0–1.4) 1.4 (1.2–1.8)
Age** 2,596 – 0.8 (0.8–0.9) 0.8 (0.8–0.9) 2,596 – 0.9 (0.8–1.0) 0.9 (0.8–1.0)
Year of ART Start
{ 2,596 – 1.6 (1.2–2.0) 1.5 (1.2–1.8) 2,596 – 1.1 (1.0–1.2) 1.1 (0.9–1.2)
Married
Married/Living together 1,211 21.2 1.0 1.0 1,211 12.4 1.0 1.0
Single/Widowed 1,152 18.3 0.9 (0.8–1.0) 0.9 (0.8–1.1) 1,152 15.7 1.3 (1.1–1.4) 1.3 (1.2–1.5)
Employed
Yes 992 18.8 1.0 1.0 992 13.4 1.0 1.0
Student 107 18.8 1.1 (0.7–1.5) 1.0 (0.7–1.4) 107 15.8 1.2 (0.9–1.5) 1.0 (0.7–1.5)
No 1,169 20.8 1.1 (0.8–1.4) 1.1 (0.9–1.3) 1,169 14.4 1.1 (0.9–1.3) 1.1 (0.8–1.4)
Active TB
No 2,297 18.9 1.0 1.0 2,297 14.0 1.0 1.0
Yes 267 27.9 1.4 (1.0–2.0) 1.0 (0.8–1.4) 267 13.9 1.0 (0.8–1.3) 1.0 (0.7–1.3)
WHO Stage
Stage I/II 619 13.3 1.0 1.0 619 14.6 1.0 1.0
Stage III 739 21.7 1.5 (1.2–2.0) 1.1 (0.8–1.6) 739 13.1 0.9 (0.7–1.2) 0.9 (0.6–1.2)
Stage IV 259 35.0 2.5 (1.9–3.2) 1.7 (1.3–2.4) 259 14.7 1.0 (0.7–1.4) 0.9 (0.6–1.3)
Weight
.60 470 12.7 1.0 1.0 470 11.7 1.0
45–60 1,224 18.1 1.4 (1.1– 1.8) 1.2 (1.0–1.6) 1,224 14.3 1.2 (1.0–1.5) 1.3 (1.0–1.7)
,45 367 41.9 2.9 (2.2–3.8) 2.1 (1.6–2.9) 367 17.5 1.5 (1.0–2.3) 1.6 (1.0–2.6)
CD4
+ T-cell count (cells/mL)
.200 754 18.8 1.0 – 754 16.7 1.0 –
.50–#200 1,144 18.5 1.0 (0.8–1.3) – 1,144 10.2 0.6 (0.5–0.8) –
,50 356 25.8 1.4 (1.1–1.8) – 356 22.1 1.3 (1.0–1.8) –
Hemoglobin
$8.0 g/dL 1,664 17.2 1.0 1.0 1,664 14.0 1.0 1.0
,8.0 g/dL 235 40.5 2.2 (1.7–2.8) 1.6 (1.2–2.1) 235 14.1 1.0 (0.7–1.5) 0.9 (0.6–1.5)
Prescribed CTX
Yes 821 15.3 1.0 1.0 821 13.7 1.0 1.0
No 1,775 21.9 1.4 (1.1–1.8) 1.4 (1.0–1.8) 1,775 14.1 1.0 (0.9–1.2) 1.0 (0.9–1.2)
Adherence
$95% 1,263 17.0 1.0 1.0 1,263 13.4 1.0 1.0
,95% 597 28.3 1.5 (1.0–2.3) 1.3 (0.8–2.0) 597 15.8 1.2 (0.9–1.6) 1.2 (0.9–1.6)
Site Size
.1,000 patients 2,109 15.9 1.0 1.0 2109 13.8 1.0 1.0
#1,000 patients 487 37.3 2.1 (1.1–3.8) 1.5 (0.8–2.6) 487 14.6 1.0 (0.7–1.5) 1.0 (0.6–1.5)
Abbreviations: Rate/100PY, rate per 100 person-years; HR, hazards ratio; AHR, adjusted hazards ratio; CI, confidence interval; TB, tuberculosis; WHO, World Health
Organization; BMI, body mass index; CTX, co-trimoxazole.
*Stratified by CD4
+ T-cell count (cells/mL).
{All variables listed in this table were included in the multivariate Cox proportional hazards regression model.
**Hazard ratios associated with a 10-year increase in age.
{Date of ART initiation was entered into the model; hazard ratios represent a yearly increase rather than a daily increase.
doi:10.1371/journal.pone.0018453.t002
Four-Year Adult ART Outcomes, Mozambique
PLoS ONE | www.plosone.org 5 April 2011 | Volume 6 | Issue 4 | e18453of therapy. Proportions of female and male ART patients who
were $95% adherent to ART were not significantly different
(72% vs. 70%, p=0.12).
Discussion
This study adds to the limited number of nationally represen-
tative ART outcome assessments from sub-Saharan Africa
[6,12,13], and has several important findings.
First, rates of mortality, attrition, and immunologic treatment
failure for the study period are comparable with reports from other
ART programs in resource-rich [9] and -constrained settings
[6,9,11,13,17,18], which is encouraging for program funders and
managers. Second, regimen-switch rates were very low, a finding
which deserves further research as it possibly indicates delay in
switching patients from failing first-line regimens and risk of poor
longer term outcomes [20]. Third, as has been reported from
other ART programs, male sex, advanced HIV disease, and
malnutrition predicted poor outcomes, suggesting that male-
specific interventions, starting ART at earlier disease stages, and
evidence-based interventions for malnourished patients, could
Figure 1. Kaplan-Meier Analysis (imputed dataset 1).
doi:10.1371/journal.pone.0018453.g001
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doi:10.1371/journal.pone.0018453.g002
Figure 3. Modeled changes in weight over time for surviving patients initiating ART during 2004–2007.
doi:10.1371/journal.pone.0018453.g003
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ART initiation, which was documented for about one third of
patients, was associated with lower attrition risk, highlighting the
need for CTX scale-up among ART patients [32–35]. Fifth,
attrition rates appeared to increase as the ART program
expanded, a concerning trend that requires further research to
better understand underlying causes. Finally, documenting partner
sero-status was uncommon, possibly indicating missed prevention
opportunities among sero-discordant couples [36].
Treatment Outcomes
Meta-analyses of attrition in adult ART programs in sub-
Saharan Africa have reported mean one-year attrition proportions
of 25% and 20% for the review periods of 2000-2007 [11] and
2007–2009 [18], respectively. In these studies, LTFU accounted
for between 56% [11] and 59% [18] of attrition. Similarly, in our
study, one-year attrition was 21% with LTFU accounting for most
(71%) of patient loss from the program. This relatively high
contribution of LTFU to attrition likely reflects the lack of active
patient tracing systems in most Mozambican ART facilities [9,37]
due to their cost [37].
Since recent reports show that patient death may account for
29–59% of patients who are LTFU [38–42], we should consider
our reported mortality and attrition rates as best- and worst-case
estimates of true mortality. Our best-case estimate of mortality (3.4
deaths per 100 person-years) is similar to reports from adult ART
programs with passive follow-up systems (2.7 deaths per 100
patient-years [9]) but predictably lower than that reported for
programs with active follow-up systems (5.5 deaths per 100
patient-years [9]). Our worst case estimate for true mortality (19.8
deaths per 100 person-years) is comparable with the rate of 16.1
deaths per 100 patient-years reported for a large Zambian cohort
[6].
Similar to other programs [4–6,8–10,13,17,43–50], large
proportions of documented mortality (56%) and LTFU (41%)
occurred within 90 days of starting ART, highlighting the
importance of this time period. Evidence based interventions
which reduce early mortality are urgently needed [51]. To limit
early LTFU from the program, the MOH is considering a pilot
program to rapidly trace all patients LTFU in the 90 days
following ART initiation.
Post 90-day mortality and attrition rates of 1.8 and 13.2 events
per 100 patient-years, respectively, are comparable with post 90-
day mortality rates reported from both resource-constrained
[6,9,17] and –rich [9] settings (5.0–6.0 deaths per 100 patient-
years). Similarly, CD4 count and weight gains [6,9,13,17], and
rates of immunologic treatment failure [6,17,52], are similar to
those reported from other ART programs.
Rates of Regimen-Switch
Compared with the average regimen-switch rate for resource-
constrained programs (2.4 switches per 100 person-years, 95% CI,
2.2–2.6 [20]), our switch rate (0.6 regimen changes per 100
person-years) was low. Limited access to routine viral load testing
has likely contributed to low regimen-switch rates [20]. However,
even compared with regimen-switch rates among programs
lacking routine viral load testing (2.0 per 100 person-years, 95%
CI 1.8–2.3 [20]), our switch rates are low. Limited access to
second-line therapy, or training in its use, may have contributed to
low switch rates, especially at more peripheral health facilities
where ART is commonly managed by non-physician clinicians
[20,53]. Because low regimen-switch rates may indicate delay in
switching patients from failing first-line regimens, which could lead
to poor long-term outcomes [20,54] further research to better
understand the reasons for low regimen-switch rates is planned.
Advanced HIV Disease
Similar to other reports, many patients initiated ART with
WHO stage IV disease, which was a strong predictor of attrition
[5,6,9,44,47,49,55–57]. This suggests that earlier diagnosis and
ART is needed to improve program outcomes [51]. Mass HIV
testing campaigns, earlier entry into HIV care, and ensuring pre-
ART care retention, will likely be needed to reduce absolute
numbers of late starters [51]. In addition, the MOH raised the
CD4 count threshold for ART initiation among adults with WHO
stage I/II disease from 200 to 250/mL in 2008, and from 250 to
350/mL in 2010 [58], which should reduce the proportion of
patients initiating ART with end-stage disease.
Male Sex
Similar to other reports [5,6,8,10,55], male sex was associated
with poorer outcomes. In our study, males tended to initiate ART
at lower CD4 counts than females, suggesting late presentation
contributed to poorer outcomes. However, even in multivariate
analysis, male sex was associated with poorer outcomes. Reasons
for this are unknown, but could relate to differences in health-
seeking or adherence behavior [59].
Malnutrition
As in other studies, our marker for malnutrition at ART
initiation (weight ,45 kg [60]) was independently associated with
poor outcomes. In Mozambique, the relative importance of
underlying causes of malnutrition among HIV-infected persons is
not well understood and deserves further research [61]. Food
supplementation and empiric TB treatment for malnourished
patients are interventions which require evaluation [62].
Failure to Prescribe CTX
Although CTX prescription is recommended for all ART
patients in Mozambique throughout therapy, few (31%) received
this drug at ART initiation during 2004–2007. Reasons for this are
unknown but may include CTX supply shortfalls and clinician
concerns about CTX drug resistance development [32,33,63].
Although several studies have demonstrated an additional
benefit of CTX for ART patients [32–35], reasons for this are
not fully understood [32]. In Mozambique, where malaria is an
important cause of mortality among ART patients [64], the
prophylactic action of CTX against this disease [32], may partly
explain its association with improved treatment outcomes.
Additional in-service training for ART-service providers is
planned to rapidly scale-up CTX prescription. Further, CTX
procurement and distribution procedures are being reviewed
to ensure that all ART delivery sites have adequate CTX
supplies.
Temporal Trends in Attrition
As the ART program expanded during 2004 through 2007,
attrition risk for newly enrolled adult ART patients increased, a
temporal trend which has been observed in other programs in
resource-constrained settings [65,66]. Yearly increases in observed
LTFU due to undocumented transfer of patients to more
peripheral facilities during the decentralization process, may
explain the increases in observed attrition rates [67,68]; however,
further research to establish the reasons for increasing rates of
attrition is urgently needed [65].
Four-Year Adult ART Outcomes, Mozambique
PLoS ONE | www.plosone.org 8 April 2011 | Volume 6 | Issue 4 | e18453Partner HIV Counseling and Testing
The low proportion of records with documented partner sero-
status is concerning because partner HIV counseling and testing
(HIV-CT) can facilitate entry into HIV care for infected
individuals or appropriate prevention strategies for uninfected
partners [36,69–76]. Poor completion of the partner sero-status
field in standard MOH medical records may be due to several
barriers including hesitancy of patients to disclose HIV status,
partner refusal to be tested, or loss to follow-up of the patient
before the field can be filled. Further research to identify and
overcome these barriers is needed.
Limitations
Limitations primarily relate to the fact that these analyses were
based on routinely collected data, which were incomplete for
certain baseline and follow-up clinical characteristics.
Summary
Treatment outcomes were comparable with reports from other
ART programs; however, the low ART regimen-switch rates and
the increasing attrition rates during program expansion are
concerning findings which deserve further research. Immediate
public health responses that may improve treatment outcomes
include initiation of ART at earlier disease stages, especially
among males, scale-up of CTX, and evidence-based interventions
for malnourished patients; in addition, scale-up of partner HIV-
CT could significantly contribute to national HIV prevention
efforts.
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